MICROFLUIDIC MARKET ANALYSIS

Microfluidic Market, By Product Type (Microfluidic-Based Devices and Microfluidic Components), By Material (Polymer, Glass, Silicon, Metal, Ceramics), By Application (Point of care testing, Clinical Diagnostics, Drug Delivery, Analytical Testing, Genomics, Proteomics, Cell based Analysis, Others), By End User (Hospitals & Diagnostic Centers, Academic & Research Institute, Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Jul 2024
Code : CMI1086
Pages :161
Formats :
Excel and PDF
Industry : Medical Devices

Key Developments

In November 2023, Microfluidics, a division of IDEX Material Processing Technology (MPT), introduced its latest processor tailored for large-scale cell disruption. This technology is crucial in the production of various biological products, including antigens for vaccines and viral vectors used in advanced gene therapy
In January 2023, SCIEX unveiled the Intabio ZT system, marking the debut of a fully integrated platform based on microfluidic chip technology. It combines imaged capillary isoelectric focusing (icIEF) separation with UV detection capabilities.
In July 2023, Biotech Fluidics unveiled new low-volume online degassing modules designed specifically for nano and microfluidic systems. These modules find applications in drug screening, nucleic acid sequencing, diagnostics, and tissue culture.
In August 2022, researchers at the School of Electrical and Computer Engineering in Atlanta, USA, introduced the Cluster-Well chip. This innovative microfluidic chip harnesses precision to detect metastatic cancer, facilitating swift and straightforward cancer treatment interventions.
In July 2020, Fluidigm Corporation entered into a letter contract with the National Institute of Biomedical Imaging and Bioengineering and the National Institutes of Health under the Rapid Acceleration of Diagnostics program. This initiative, with a proposed total budget of up to USD 37 million, aimed to enhance the manufacturing capabilities and production capacity of COVID-19 testing using Fluidigm's microfluidics technology.